Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity

다국어 초록 (Multilingual Abstract)

Background To estimate real-world outcomes in East Asian populations, we conducted a nationwide retrospective analysis of the efficacy and safety of lenalidomide for del(5q) myelodysplastic syndrome (MDS) patients with transfusion-dependent anemia in Korea.
Methods Patients aged ≥19 years who had received lenalidomide for the treatment of lower-risk, red blood cell (RBC) transfusion-dependent del(5q) MDS were selected. A filled case report form (CRF) with information from electronic medical records was requested from members of the acute myeloid leukemia (AML)/MDS Working Party of the Korean Society of Hematology. All the CRFs were gathered and analyzed.
Results A total of 31 patients were included in this study. Of 28 evaluable patients, 19 (67.9%) achieved RBC transfusion independence (RBC-TI). Female sex and the development of thrombocytopenia during treatment were associated with achieving RBC-TI. The most common non-hematologic toxicities were pruritus, fatigue, and rashes. All non-hematologic toxicities of grades ≥3 were limited to rash (12.9%) and pruritus (6.5%). Dose reduction was required in 15 of the 19 responders (78.9%). The most common final stable dosing schedule for the responders was 5 mg once every other day (31.6%).
Conclusion Lenalidomide efficacy and tolerability were similar in the Asian del(5q) MDS patients and western patients. Dose reduction during treatment was common, but it was not associated with inferior outcomes.

참고문헌 (Reference)

1 Adema V, "What lies beyond del(5q)in myelodysplastic syndrome" 98 : 1819-1821, 2013

2 Kelaidi C, "Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide" 32 : 1049-1053, 2008

3 Le Bras F, "Treatment by lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience" 35 : 1444-1448, 2011

4 최은지, "Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome" 대한혈액학회 53 (53): 288-293, 2018

5 Sperling AS, "The genetics of myelodysplastic syndrome : from clonal haematopoiesis to secondary leukaemia" 17 : 5-19, 2017

6 Arber DA, "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia" 127 : 2391-2405, 2016

7 Greenberg PL, "Revised international prognostic scoring system for myelodysplastic syndromes" 120 : 2454-2465, 2012

8 Cazzola M, "Myelodysplastic syndromes" 3833 : 1358-1374, 2020

9 Harada H, "Lenalidomide is active in Japanese patients with symptomatic anemia in low-or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality" 90 : 353-360, 2009

10 List A, "Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion" 355 : 1456-1465, 2006

11 Kuendgen A, "Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low-or Intermediate-1-risk MDS with del(5q) : a comparative analysis" 27 : 1072-1079, 2013

12 Greenberg P, "International scoring system for evaluating prognosis in myelodysplastic syndromes" 89 : 2079-2088, 1997

13 Hong J, "Incidence of venous thromboembolism in Korea from 2009 to 2013" 13 : e0191897-, 2018

14 Fenaux P, "How we treat lower-risk myelodysplastic syndromes" 121 : 4280-4286, 2013

15 Miyazaki Y, "Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes : analysis from the International Working Group for Prognosis of MDS" 73 : 51-57, 2018

16 Haase D, "Cytogenetic features in myelodysplastic syndromes" 87 : 515-526, 2008

17 Pan WH, "Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks : implications for definitions of overweight and obesity for Asians" 79 : 31-39, 2004

18 Lee JH, "Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome" 17 : 305-313, 2003

19 Boultwood J, "Advances in the 5q-syndrome" 116 : 5803-5811, 2010

20 Fenaux P, "A randomized phase 3 study of lenalidomide versus placebo in RBC transfusiondependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q" 118 : 3765-3776, 2011